drugset / Trial / NCT04863131
Safety and Immunogenicity of EXG-5003
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This is a First in Human, randomized, placebo-controlled Phase I/II trial to evaluate the safety and immunogenicity of the intradermal COVID-19 vaccine, EXG-5003 in healthy adults.
Timeline
- Start
- 2021-04-28
- Primary completion
- 2022-12-31
- Completion
- 2023-01-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EXG-5003 | Messenger RNA (mRNA) | — | Other |